These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

326 related articles for article (PubMed ID: 25505789)

  • 41. Therapeutic targeting of mTOR in tuberous sclerosis.
    Sampson JR
    Biochem Soc Trans; 2009 Feb; 37(Pt 1):259-64. PubMed ID: 19143643
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Pulmonary lymphangioleiomyomatosis in tuberous sclerosis. A case report.
    De Rosa N
    Pathologica; 2009 Oct; 101(5):186-9. PubMed ID: 20218060
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Pulmonary Lymphangioleiomyomatosis originates in the pleural mesothelial cell population.
    Clements D; Miller S; Johnson SR
    Med Hypotheses; 2020 Aug; 141():109703. PubMed ID: 32276237
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Circulating Lymphangioleiomyomatosis Tumor Cells With Loss of Heterozygosity in the TSC2 Gene Show Increased Aldehyde Dehydrogenase Activity.
    Pacheco-Rodríguez G; Steagall WK; Samsel L; Dagur PK; McCoy JP; Tunc I; Pirooznia M; Wang JA; Darling TN; Moss J
    Chest; 2019 Aug; 156(2):298-307. PubMed ID: 31034819
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Lymphangioleiomyomatosis and Tuberous Sclerosis Complex in Quebec: Prevalence and Health-care Utilization.
    Kristof AS; Zhi Li P; Major P; Landry JS
    Chest; 2015 Aug; 148(2):444-449. PubMed ID: 25789699
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Lymphangioleiomyomatosis and TSC2-/- cells.
    Darling TN; Pacheco-Rodriguez G; Gorio A; Lesma E; Walker C; Moss J
    Lymphat Res Biol; 2010 Mar; 8(1):59-69. PubMed ID: 20235888
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Anti-EGFR antibody reduces lung nodules by inhibition of EGFR-pathway in a model of lymphangioleiomyomatosis.
    Lesma E; Chiaramonte E; Ancona S; Orpianesi E; Di Giulio AM; Gorio A
    Biomed Res Int; 2015; 2015():315240. PubMed ID: 25699271
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Exploring the Role of Matrix Metalloproteinases as Biomarkers in Sporadic Lymphangioleiomyomatosis and Tuberous Sclerosis Complex. A Pilot Study.
    Terraneo S; Lesma E; Ancona S; Imeri G; Palumbo G; Torre O; Giuliani L; Centanni S; Peron A; Tresoldi S; Cetrangolo P; Di Marco F
    Front Med (Lausanne); 2021; 8():605909. PubMed ID: 33981713
    [No Abstract]   [Full Text] [Related]  

  • 49. Chromosome 16 loss of heterozygosity in tuberous sclerosis and sporadic lymphangiomyomatosis.
    Yu J; Astrinidis A; Henske EP
    Am J Respir Crit Care Med; 2001 Oct; 164(8 Pt 1):1537-40. PubMed ID: 11704609
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Sporadic lymphangioleiomyomatosis and tuberous sclerosis complex with lymphangioleiomyomatosis: comparison of CT features.
    Avila NA; Dwyer AJ; Rabel A; Moss J
    Radiology; 2007 Jan; 242(1):277-85. PubMed ID: 17105849
    [TBL] [Abstract][Full Text] [Related]  

  • 51. EPIDEMIOLOGY, PATHOGENESIS and DIAGNOSIS of LYMPHANGIOLEIOMYOMATOSIS.
    Taveira-DaSilva AM; Moss J
    Expert Opin Orphan Drugs; 2016; 4(4):369-378. PubMed ID: 27833825
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The role of chemokines in migration of metastatic-like lymphangioleiomyomatosis cells.
    Pacheco-Rodriguez G; Moss J
    Crit Rev Immunol; 2010; 30(4):387-94. PubMed ID: 20666708
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Women with TSC: Relationship between Clinical, Lung Function and Radiological Features in a Genotyped Population Investigated for Lymphangioleiomyomatosis.
    Di Marco F; Terraneo S; Imeri G; Palumbo G; La Briola F; Tresoldi S; Volpi A; Gualandri L; Ghelma F; Alfano RM; Montanari E; Gorio A; Lesma E; Peron A; Canevini MP; Centanni S
    PLoS One; 2016; 11(5):e0155331. PubMed ID: 27171001
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Lymphangioleiomyomatosis: a review of the literature.
    Hancock E; Osborne J
    Respir Med; 2002 Jan; 96(1):1-6. PubMed ID: 11863203
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Differential Modulation of Matrix Metalloproteinases-2 and -7 in LAM/TSC Cells.
    Ancona S; Orpianesi E; Bernardelli C; Chiaramonte E; Chiaramonte R; Terraneo S; Di Marco F; Lesma E
    Biomedicines; 2021 Nov; 9(12):. PubMed ID: 34944575
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Pulmonary lymphangioleiomyomatosis (LAM): progress and current challenges.
    Goncharova EA; Krymskaya VP
    J Cell Biochem; 2008 Feb; 103(2):369-82. PubMed ID: 17541983
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Extrapulmonary lymphangioleiomyomatosis and lymphangiomatous cysts in tuberous sclerosis complex.
    Torres VE; Björnsson J; King BF; Kumar R; Zincke H; Edell ES; Wilson TO; Hattery RR; Gomez MR
    Mayo Clin Proc; 1995 Jul; 70(7):641-8. PubMed ID: 7791386
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Prevalence and clinical characteristics of lymphangioleiomyomatosis (LAM) in patients with tuberous sclerosis complex.
    Moss J; Avila NA; Barnes PM; Litzenberger RA; Bechtle J; Brooks PG; Hedin CJ; Hunsberger S; Kristof AS
    Am J Respir Crit Care Med; 2001 Aug; 164(4):669-71. PubMed ID: 11520735
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Evidence Supporting a Lymphatic Endothelium Origin for Angiomyolipoma, a TSC2(-) Tumor Related to Lymphangioleiomyomatosis.
    Yue M; Pacheco G; Cheng T; Li J; Wang Y; Henske EP; Schuger L
    Am J Pathol; 2016 Jul; 186(7):1825-1836. PubMed ID: 27289491
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A Comparison of Clinical and Radiological Presentations of Sporadic and Tuberous Sclerosis Complex-Associated Lymphangioleiomyomatosis.
    Savage TE; Geenen KR; Price MC; El-Chemaly SY; Henske EP; Sharma A; Thiele EA
    Am J Med Genet A; 2024 Sep; ():e63871. PubMed ID: 39243170
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.